T1	tradename 139 146	MACUGEN
T2	tradename 208 215	MACUGEN
T3	tradename 217 224	MACUGEN
T4	nanoparticle 225 235	pegaptanib
T5	routeofadministration 254 266	Intravitreal
T6	fdaapprovaldate 300 304	2004
T7	tradename 364 371	Macugen
T8	indication 406 456	neovascular (wet) age-related macular degeneration
T9	routeofadministration 538 550	INTRAVITREAL
T10	tradename 584 591	Macugen
T11	dose 592 598	0.3 mg
T12	frequency 622 643	once every six weeks
T13	routeofadministration 647 660	intravitreous
T14	dose 764 771	0.3 mg/
T15	routeofadministration 814 826	intravitreal
T16	adversereaction 912 943	Ocular or periocular infections
T17	adversereaction 961 977	Hypersensitivity
T18	adversereaction 1046 1061	Endophthalmitis
T19	routeofadministration 1082 1095	intravitreous
T20	tradename 1189 1197	Macugen.
T21	tradename 1368 1375	Macugen
T22	adversereaction 1408 1444	anaphylaxis/anaphylactoid reactions,
T23	adversereaction 1455 1466	angioedema,
T24	tradename 1659 1666	Macugen
T25	adversereaction 1693 1983	anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure (IOP), ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters,
T26	adversereaction 1988 2006	vitreous opacities
T27	company 2062 2074	Eyetech Inc.
T28	tradename 2084 2091	MACUGEN
T29	adversereaction 2855 2870	Endophthalmitis
T30	adversereaction 2912 2945	Increases in Intraocular Pressure
T31	tradename 3355 3362	Macugen
T32	indication 3397 3434	neovascular (wet) age-related macular
T33	routeofadministration 3526 3538	INTRAVITREAL
T34	tradename 3567 3574	Macugen
T35	dose 3575 3581	0.3 mg
T36	frequency 3605 3625	once every six weeks
T37	routeofadministration 3629 3642	intravitreous
T38	tradename 3717 3724	Macugen
T39	routeofadministration 6024 6036	intravitreal
T40	adversereaction 6164 6197	elevation in intraocular pressure
T41	adversereaction 6206 6222	endophthalmitis.
T42	adversereaction 6506 6521	endophthalmitis
T43	tradename 6683 6690	Macugen
T44	dose 6901 6907	0.3 mg
T45	tradename 6911 6918	Macugen
T46	routeofadministration 6950 6962	intravitreal
T47	tradename 7031 7038	Macugen
T48	tradename 7132 7139	Macugen
T49	nanoparticle 7202 7212	pegaptanib
T50	adversereaction 7292 7307	Endophthalmitis
T51	routeofadministration 7308 7321	Intravitreous
T52	tradename 7355 7363	Macugen,
T53	adversereaction 7390 7406	endophthalmitis.
T54	tradename 7488 7496	Macugen.
T55	adversereaction 7676 7743	Increases in Intraocular Pressure Increases in intraocular pressure
T56	tradename 7795 7803	Macugen.
T57	adversereaction 7974 7985	Anaphylaxis
T58	adversereaction 8000 8036	anaphylaxis/anaphylactoid reactions,
T59	adversereaction 8047 8058	angioedema,
T60	tradename 8125 8132	Macugen
T61	routeofadministration 8133 8145	intravitreal
T62	routeofadministration 8362 8375	intravitreous
T63	adversereaction 8396 8411	endophthalmitis
T64	adversereaction 8450 8469	retinal detachment,
T65	adversereaction 8474 8504	iatrogenic traumatic cataract.
T66	tradename 8607 8614	Macugen
T67	dose 8615 8621	0.3 mg
T68	adversereaction 8647 8937	anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure (IOP), ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters,
T69	adversereaction 8942 8961	vitreous opacities.
T70	tradename 9089 9096	Macugen
T71	dose 9097 9103	0.3 mg
T72	adversereaction 9122 9180	blepharitis, conjunctivitis, photopsia, vitreous disorder.
T73	adversereaction 9194 9269	bronchitis, diarrhea, dizziness, headache, nausea, urinary tract infection.
T74	tradename 9398 9405	Macugen
T75	dose 9406 9412	0.3 mg
T76	adversereaction 9432 9696	allergic conjunctivitis, conjunctival edema, corneal abrasion, corneal deposits, corneal epithelium disorder, endophthalmitis, eye inflammation, eye swelling, eyelid irritation, meibomianitis, mydriasis, periorbital hematoma, retinal edema, vitreous hemorrhage.
T77	adversereaction 9711 9956	arthritis, bone spur, carotid artery occlusion, cerebrovascular accident, chest pain, contact dermatitis, contusion, diabetes mellitus, dyspepsia, hearing loss, pleural effusion, transient ischemic attack, urinary retention, vertigo, vomiting.
T78	adversereaction 9988 10024	Anaphylaxis/anaphylactoid reactions,
T79	adversereaction 10035 10046	angioedema,
T80	tradename 10095 10103	Macugen.
T81	nanoparticle 10468 10478	Pegaptanib
T82	routeofadministration 10573 10584	intravenous
T83	dose 10600 10608	40 mg/kg
T84	frequency 10608 10612	/day
T85	dose 10683 10690	0.3 mg/
T86	nanoparticle 10696 10706	Pegaptanib
T87	nanoparticle 11009 11019	pegaptanib
T88	tradename 11127 11134	Macugen
T89	tradename 11218 11225	Macugen
T90	tradename 11351 11358	Macugen
T91	tradename 11562 11569	Macugen
T92	dose 11611 11617	0.3 mg
T93	dose 11732 11737	1 mg.
T94	tradename 11817 11824	Macugen
T95	nanoparticle 11826 11836	pegaptanib
T96	nanoparticle 11897 11907	pegaptanib
T97	routeofadministration 11919 11932	intravitreous
T98	tradename 11945 11952	Macugen
T99	activeingredient 12084 12100	oligonucleotide.
T100	dose 12126 12132	0.3 mg
T101	activeingredient 12162 12177	oligonucleotide
T102	surfacecoating 12186 12206	polyethylene glycol,
T103	nanoparticle 12274 12284	pegaptanib
T104	surfacecoating 12293 12302	pegylated
T105	activeingredient 12303 12319	oligonucleotide)
T106	activeingredient 12377 12392	oligonucleotide
T107	inactiveingredient 12473 12587	sodium chloride, monobasic sodium phosphate monohydrate, dibasic sodium phosphate heptahydrate, hydrochloric acid,
T108	inactiveingredient 12595 12611	sodium hydroxide
T109	nanoparticle 12655 12665	Pegaptanib
T110	activeingredient 12703 12746	oligonucleotide of twenty-eight nucleotides
T111	molecularweight 12811 12824	20-kilodalton
T112	surfacecoating 12825 12862	monomethoxy polyethylene glycol (PEG)
T113	nanoparticle 12940 12950	Pegaptanib
T114	nanoparticle 13151 13161	pegaptanib
T115	nanoparticle 13743 13753	pegaptanib
T116	molecularweight 13872 13887	50 kilodaltons.
T117	tradename 13890 13897	Macugen
T118	nanoparticle 14022 14032	Pegaptanib
T119	indication 14392 14450	neovascular (wet) form of age-related macular degeneration
T120	nanoparticle 14594 14604	Pegaptanib
T121	surfacecoating 14622 14631	pegylated
T122	activeingredient 14641 14657	oligonucleotide,
T123	nanoparticle 14787 14797	pegaptanib
T124	nanoparticle 15102 15112	pegaptanib
T125	routeofadministration 15181 15194	intravitreous
T126	nanoparticle 15296 15306	pegaptanib
T127	cmax 15430 15438	80 ng/mL
T128	tmax 15453 15464	1 to 4 days
T129	dose 15473 15477	3 mg
T130	auc 15598 15607	25 ghr/mL
T131	nanoparticle 15623 15633	Pegaptanib
T132	tradename 15786 15793	Macugen
T133	nanoparticle 15917 15928	pegaptanib.
T134	routeofadministration 16067 16080	intravitreous
T135	nanoparticle 16122 16132	pegaptanib
T136	routeofadministration 16247 16260	intravitreous
T137	routeofadministration 16265 16276	intravenous
T138	nanoparticle 16309 16319	pegaptanib
T139	routeofadministration 16403 16416	intravitreous
T140	nanoparticle 16562 16572	pegaptanib
T141	routeofadministration 16573 16584	intravenous
T142	routeofadministration 16589 16602	intravitreous
T143	nanoparticle 16622 16632	pegaptanib
T144	nanoparticle 16730 16740	pegaptanib
T145	dose 16803 16807	3 mg
T146	nanoparticle 16919 16929	pegaptanib
T147	plasmahalflife 16933 16945	10 (4) days.
T148	nanoparticle 17210 17220	pegaptanib
T149	nanoparticle 17369 17379	Pegaptanib
T150	nanoparticle 17532 17543	Pegaptanib,
T151	nanoparticle 17882 17893	Pegaptanib,
T152	tradename 17979 17986	Macugen
T153	indication 18094 18110	neovascular AMD.
T154	dose 18176 18188	0.3 mg, 1 mg
T155	dose 18192 18196	3 mg
T156	tradename 18197 18204	Macugen
T157	routeofadministration 18221 18234	intravitreous
T158	tradename 18356 18363	Macugen
T159	indication 18791 18806	neovascular AMD
T160	tradename 19329 19336	Macugen
T161	dose 19337 19343	0.3 mg
T162	tradename 19464 19471	Macugen
T163	tradename 19505 19512	Macugen
T164	tradename 19626 19633	Macugen
T165	dose 19634 19640	0.3 mg
T166	tradename 19681 19688	Macugen
T167	dose 19689 19695	0.3 mg
T168	tradename 19820 19827	Macugen
T169	tradename 20175 20182	Macugen
T170	tradename 20355 20362	Macugen
T171	tradename 20409 20416	Macugen
T172	dose 20583 20589	0.3 mg
T173	tradename 20662 20669	Macugen
T174	tradename 20750 20757	Macugen
T175	nanoparticle 20759 20769	pegaptanib
T176	dose 20870 20876	0.3 mg
T177	tradename 20880 20887	Macugen
T178	tradename 21279 21286	Macugen
T179	tradename 21558 21565	MACUGEN
T180	nanoparticle 21566 21576	pegaptanib
T181	company 21614 21634	Gilead Sciences, Inc
T182	company 21684 21696	Eyetech Inc.
T183	company 21821 21847	Becton Dickinson &amp; CO,
